Provided by Tiger Trade Technology Pte. Ltd.

Horizon Kinetics Blockchain Development ETF

32.21
+0.21970.69%
Post-market: 31.99-0.2197-0.68%16:10 EDT
Volume:57
Turnover:2K
Market Cap:23.35M
PE:- -
High:32.21
Open:31.99
Low:32.21
Close:31.99
52wk High:36.27
52wk Low:29.01
Shares:725.00K
Float Shares:725.00K
Volume Ratio:0.03
T/O Rate:0.01%
Dividend:0.76
Dividend Rate:2.37%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

KULR Receives over $1 Million in Battery Orders for U.S. Defense Drone Program

Reuters
·
Oct 01

SAB Biotherapeutics Presents Phase 1 Data for SAB-142 Immunotherapy in Stage 3 Type 1 Diabetes at CRC 2026

Reuters
·
Oct 01

Helport AI White Paper Flags Shift from Task Automation to Measurable “AI Labor” in Enterprise Workflows

Reuters
·
Oct 01

Birchtech Names Charlie Cooper Business Development Manager for Rural, Small Water Systems

Reuters
·
Oct 01

Cloudastructure Expands Housing Partner Deployment to Nine Properties

Reuters
·
Oct 01

Nuwellis Attends Four October Medical Conferences to Showcase Aquadex Fluid Management System

Reuters
·
Oct 01

RBB Bancorp Updates Financial Calendar with Quarterly Results Release and Conference Call

Reuters
·
Oct 01

RenovoRx Cites Peer-Reviewed Case Series on TAMP Gemcitabine Delivery in Locally Advanced Pancreatic Cancer

Reuters
·
Oct 01

Conifex Names Spencer Bell CFO, Corporate Secretary Effective Oct. 1, 2026

Reuters
·
Oct 01

Roper Technologies Schedules Q3 2026 Results Conference Call

Reuters
·
Oct 01

Spectral AI Launches DeepView Clinical Study to Support FDA Label Expansion for Head, Hands and Feet Burns

Reuters
·
Oct 01

Nexalin Technology Signs Exclusive South America Distribution Pact with Inovanexa Medical Technologies

Reuters
·
Oct 01

ZenaTech Joins Russell 3000 Index

Reuters
·
Oct 01

Akari Therapeutics Files PCT Patent Application for PH1 RNA-Splicing ADC Payload in Cancer

Reuters
·
Oct 01

Reliance Global Group Sells Altruis Benefit Consulting for $8 Million Cash Plus up to $1 Million Earnout

Reuters
·
Oct 01

Candel Therapeutics Phase 2a NSCLC Study Shows 24.5-Month Median Overall Survival for Aglatimagene Plus Valacyclovir After ICI Failure

Reuters
·
Oct 01

Harmony Biosciences Presents Phase 3 HBS-301 Trial Data in Narcolepsy, Idiopathic Hypersomnia at European Narcolepsy Days

Reuters
·
Oct 01

BrightSpring Health Updates Financial Calendar for Third-Quarter 2026 Results Release and Call

Reuters
·
Oct 01

Pasqal Names Florence Lao Chief Legal Officer

Reuters
·
Oct 01

Eramet Plans USD 350 Million Centenario-Ratones Lithium Expansion in Argentina Under RIGI Scheme

Reuters
·
Oct 01